At present, Bachem is proud to partner with several companies to manufacture a range of unique oligonucleotides that treat a diverse range of conditions. In addition to large-scale and sustainable manufacturing, we’re seeing tangible progress in medicinal chemistry and oligonucleotide conjugation – advances and innovations that will enable the development of targeted therapeutics that have greatly improved stability. There is particular interest in backbones, ligands and other modifications that can act as tags for specific cell types and facilitate the oligonucleotide uptake by an active mechanism especially outside of the liver.